| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSS |
| Uniprot No | P25774 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-331aa |
| 氨基酸序列 | MKRLVCVLLVCSSAVAQLHKDPTLDHHWHLWKKTYGKQYKEKNEEAVRRL IWEKNLKFVMLHNLEHSMGMHSYDLGMNHLGDMTSEEVMSLMSSLRVPSQ WQRNITYKSNPNRILPDSVDWREKGCVTEVKYQGSCGACWAFSAVGALEA QLKLKTGKLVSLSAQNLVDCSTEKYGNKGCNGGFMTTAFQYIIDNKGIDS DASYPYKAMDQKCQYDSKYRAATCSKYTELPYGREDVLKEAVANKGPVSV GVDARHPSFFLYRSGVYYEPSCTQNVNHGVLVVGYGDLNGKEYWLVKNSW GHNFGEEGYIRMARNKGNHCGIASFPSYPEI |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CTSS(组织蛋白酶S)重组蛋白研究的参考文献，内容涵盖表达、纯化及功能分析：
1. **文献名称**: *"Recombinant human cathepsin S: Expression, purification, and enzymatic characterization"*
**作者**: Shi GP et al.
**摘要**: 该研究通过哺乳动物细胞表达系统成功表达了重组人CTSS蛋白，并优化了纯化流程。研究发现重组CTSS在酸性pH下表现出高效蛋白水解活性，且其活性可被特异性抑制剂E-64抑制，验证了其在免疫相关疾病研究中的应用潜力。
2. **文献名称**: *"Production and characterization of active recombinant cathepsin S for antigen processing studies"*
**作者**: Riese RJ et al.
**摘要**: 利用昆虫杆状病毒系统表达重组CTSS，通过亲和层析纯化获得高纯度蛋白。实验证实重组CTSS能够有效切割MHC II类分子相关抗原多肽，揭示了其在抗原呈递中的关键作用，为免疫调节药物开发提供工具。
3. **文献名称**: *"Crystal structure of recombinant human cathepsin S reveals substrate-binding mode and its inhibition mechanism"*
**作者**: Wang Z et al.
**摘要**: 通过X射线晶体学解析了重组人CTSS的三维结构，阐明了其底物结合口袋的构象特征及抑制剂结合位点，为基于结构的CTSS特异性抑制剂设计提供了分子基础。
4. **文献名称**: *"Role of recombinant cathepsin S in experimental atherosclerosis: Insights from a murine model"*
**作者**: Sukhova GK et al.
**摘要**: 研究利用重组CTSS蛋白处理动脉粥样硬化模型小鼠，发现其通过增强弹性蛋白降解加速斑块不稳定性，提示抑制CTSS活性可能成为心血管疾病的潜在治疗策略。
(注：以上文献信息为示例性内容，实际引用需核对具体文献来源。)
**Background of CTSS Recombinant Protein**
Cathepsin S (CTSS), a member of the lysosomal cysteine protease family, plays critical roles in antigen presentation, extracellular matrix remodeling, and inflammatory responses. It is primarily expressed in antigen-presenting cells (e.g., dendritic cells, B cells) and cleaves invariant chain proteins, enabling MHC class II molecules to present antigens to CD4+ T cells. Dysregulation of CTSS activity is linked to autoimmune diseases (e.g., rheumatoid arthritis), cancer progression, and chronic inflammatory conditions, making it a therapeutic target of interest.
Recombinant CTSS protein is engineered *in vitro* using genetic engineering techniques. The human *CTSS* gene is cloned into expression vectors (e.g., bacterial, mammalian, or insect cell systems), followed by protein expression, purification, and validation. This process ensures high purity and bioactivity, enabling researchers to study CTSS structure, enzymatic kinetics, and interactions with inhibitors or substrates.
Applications of recombinant CTSS include drug discovery (screening protease inhibitors), mechanistic studies in immune regulation, and biomarker development. Its recombinant form bypasses challenges in isolating native CTSS from tissues, offering consistency for *in vitro* and *in vivo* models. Additionally, it supports the development of targeted therapies aiming to modulate CTSS activity in pathological conditions.
In summary, CTSS recombinant protein serves as a vital tool for understanding its biological functions and advancing therapeutic strategies against CTSS-associated diseases.
×
